CEO – Sijme Zeilemaker
Over 10 years of experience in biotech companies in oncology, business development and investor relations. Building companies, pursuing industry leadership, pitching to pharma and investors.
COO & Founder – Gerben Zondag, PhD
Over 20 years of experience in biotech companies in operational and leadership roles. Strong entrepreneurial skills and scientific background in molecular biology.
CSO – Jeroen van Bergen, PhD
Cum laude PhD in tumor immunology, EMBO & VENI fellow, 25 years of experience in immunology with over 50 publications.
CFO – Remco Lont
Close to 10 years of experience in (biotech) financing and M&A, previously with ING and Kempen & Co.
Prof. Ferry Ossendorp
Synthetic Vaccine Biology and head of the Tumor Immunology group, Leiden University Medical Center.
Prof. John Haanen
Translational Immunotherapy of Cancer and head of Medical Oncology, Netherlands Cancer Institute.